Harnessing phytochemicals: Innovative strategies to enhance cancer immunotherapy

IF 21.7 1区 医学 Q1 PHARMACOLOGY & PHARMACY Drug Resistance Updates Pub Date : 2025-02-01 DOI:10.1016/j.drup.2025.101206
Qianru Zhu , Ruonan Zhang , Ziming Zhao , Tian Xie , Xinbing Sui
{"title":"Harnessing phytochemicals: Innovative strategies to enhance cancer immunotherapy","authors":"Qianru Zhu ,&nbsp;Ruonan Zhang ,&nbsp;Ziming Zhao ,&nbsp;Tian Xie ,&nbsp;Xinbing Sui","doi":"10.1016/j.drup.2025.101206","DOIUrl":null,"url":null,"abstract":"<div><div>Cancer immunotherapy has revolutionized cancer treatment, but therapeutic ineffectiveness—driven by the tumor microenvironment and immune evasion mechanisms—continues to limit its clinical efficacy. This challenge underscores the need to explore innovative approaches, such as multimodal immunotherapy. Phytochemicals, bioactive compounds derived from plants, have emerged as promising candidates for overcoming these barriers due to their immunomodulatory and antitumor properties. This review explores the synergistic potential of phytochemicals in enhancing immunotherapy by modulating immune responses, reprogramming the tumor microenvironment, and reducing immunosuppressive factors. Integrating phytochemicals with conventional immunotherapy strategies represents a novel approach to mitigating resistance and enhancing therapeutic outcomes. For instance, nab-paclitaxel has shown the potential in overcoming resistance to immune checkpoint inhibitors, while QS-21 synergistically enhances the efficacy of tumor vaccines. Furthermore, we highlight recent advancements in leveraging nanotechnology to engineer phytochemicals for improved bioavailability and targeted delivery. These innovations hold great promise for optimizing the clinical application of phytochemicals. However, further large-scale clinical studies are crucial to fully integrate these compounds into immunotherapeutic regimens effectively.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"79 ","pages":"Article 101206"},"PeriodicalIF":21.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Resistance Updates","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1368764625000068","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer immunotherapy has revolutionized cancer treatment, but therapeutic ineffectiveness—driven by the tumor microenvironment and immune evasion mechanisms—continues to limit its clinical efficacy. This challenge underscores the need to explore innovative approaches, such as multimodal immunotherapy. Phytochemicals, bioactive compounds derived from plants, have emerged as promising candidates for overcoming these barriers due to their immunomodulatory and antitumor properties. This review explores the synergistic potential of phytochemicals in enhancing immunotherapy by modulating immune responses, reprogramming the tumor microenvironment, and reducing immunosuppressive factors. Integrating phytochemicals with conventional immunotherapy strategies represents a novel approach to mitigating resistance and enhancing therapeutic outcomes. For instance, nab-paclitaxel has shown the potential in overcoming resistance to immune checkpoint inhibitors, while QS-21 synergistically enhances the efficacy of tumor vaccines. Furthermore, we highlight recent advancements in leveraging nanotechnology to engineer phytochemicals for improved bioavailability and targeted delivery. These innovations hold great promise for optimizing the clinical application of phytochemicals. However, further large-scale clinical studies are crucial to fully integrate these compounds into immunotherapeutic regimens effectively.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用植物化学物质:加强癌症免疫治疗的创新策略
癌症免疫治疗已经彻底改变了癌症治疗,但肿瘤微环境和免疫逃避机制驱动的治疗无效继续限制其临床疗效。这一挑战强调需要探索创新方法,如多模式免疫疗法。植物化学物质,从植物中提取的生物活性化合物,由于其免疫调节和抗肿瘤的特性,已经成为克服这些障碍的有希望的候选者。这篇综述探讨了植物化学物质通过调节免疫反应、重编程肿瘤微环境和减少免疫抑制因子来增强免疫治疗的协同潜力。将植物化学物质与传统免疫治疗策略相结合,是一种减轻耐药性和提高治疗效果的新方法。例如,nab-紫杉醇已显示出克服免疫检查点抑制剂耐药性的潜力,而QS-21协同增强肿瘤疫苗的效力。此外,我们强调了利用纳米技术设计植物化学物质以提高生物利用度和靶向递送的最新进展。这些创新为优化植物化学物质的临床应用提供了巨大的希望。然而,进一步的大规模临床研究对于将这些化合物有效地整合到免疫治疗方案中至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Resistance Updates
Drug Resistance Updates 医学-药学
CiteScore
26.20
自引率
11.90%
发文量
32
审稿时长
29 days
期刊介绍: Drug Resistance Updates serves as a platform for publishing original research, commentary, and expert reviews on significant advancements in drug resistance related to infectious diseases and cancer. It encompasses diverse disciplines such as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The journal addresses both basic research and clinical aspects of drug resistance, providing insights into novel drugs and strategies to overcome resistance. Original research articles are welcomed, and review articles are authored by leaders in the field by invitation. Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective. *Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research
期刊最新文献
Programmed cell death network in cancer drug resistance: a framework for therapeutic intervention The c-Myc-USP14-PFKP axis sustains chemoresistance in pancreatic ductal adenocarcinoma Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical trial. Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies Recent Advances in Near-Infrared Fluorescent Ligands as a Novel Frontier in Combating Antibiotic-Resistant Bacteria
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1